Composition for treating Alzheimer disease and preparation method thereof

An effective drug for treating Alzheimer's disease was prepared by fermenting a combination of guava, green papaya, yam, polygonatum, and amla. This solved the problem that existing technologies could not completely cure Alzheimer's disease and significantly improved patients' learning, memory, and symptoms of depression and anxiety.

CN118924844APending Publication Date: 2024-11-12段和平

Patent Information

Application Number
CN202411195753.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is currently no way to completely cure Alzheimer's disease. Long-term treatment can only control the progression of the disease. How to develop effective drugs to treat Alzheimer's disease is an urgent problem to be solved.

Method used

A composition using guava, green papaya, yam, polygonatum and amla as the main ingredients is pasteurized, pulverized and then inoculated with lactobacillus for fermentation to prepare a composition for treating Alzheimer's disease.

Benefits of technology

It significantly improves learning and memory abilities and reduces depression and anxiety levels, and has broad therapeutic effects in treating Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924844A_ABST
    Figure CN118924844A_ABST
Patent Text Reader

Abstract

The invention discloses a composition for treating Alzheimer disease. The composition comprises the following active ingredients: guava, green papaya, Chinese yam, rhizoma polygonati and emblic leafflower fruit. Meanwhile, the invention also discloses a preparation method of the composition for treating the Alzheimer disease, which comprises the following steps: taking fresh guava, green papaya, Chinese yam, rhizoma polygonati and emblic leafflower fruit, cleaning with purified water, sterilizing, crushing, inoculating lactobacillus, fermenting in a heat preservation tank, and sterilizing after ultrafiltration. The composition for treating the Alzheimer's disease can effectively play a role in improving learning and memory, depression and anxiety of patients and the like, and can be widely applied to treatment of the Alzheimer's disease, and the preparation method of the composition is simple and effective.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a composition for treating Alzheimer's disease and a preparation method thereof. Background Art

[0002] Alzheimer's disease is a degenerative disease of the central nervous system that occurs mainly in the elderly or pre-elderly. The main characteristics of the disease include progressive cognitive dysfunction and behavioral impairment, with symptoms including memory impairment, aphasia, apraxia, agnosia, and visual-spatial impairment. In addition, the patient's abstract thinking and calculation ability are also impaired, often accompanied by changes in personality and behavior.

[0003] The disease usually requires long-term treatment. Currently, the medical community mainly uses drugs and psychotherapy to control the progression of the disease and delay the deterioration of symptoms. There is no complete cure yet. In recent years, research on Alzheimer's disease has made significant progress. Genetic technology, brain imaging technology, etc. have played an important role in the early diagnosis of Alzheimer's disease, and also provided a new perspective for understanding the pathogenesis of the disease. However, the exact pathogenesis of Alzheimer's disease is still unclear, and how to effectively prevent and treat Alzheimer's disease is still a problem that needs to be explored. Therefore, it is of great significance to research and develop new and effective drugs for the treatment of Alzheimer's disease. Summary of the invention

[0004] The purpose of the present invention is to provide a composition for treating Alzheimer's disease, which can effectively treat Alzheimer's disease.

[0005] At the same time, correspondingly, the present invention also provides a method for preparing the above-mentioned composition for treating Alzheimer's disease.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A composition for treating Alzheimer's disease, characterized in that the effective ingredients of the composition for treating Alzheimer's disease include guava, green papaya, yam, polygonatum, and emblica.

[0008] Preferably, the proportion of guava is 40%; the proportion of green papaya is 30%; the proportion of yam is 20%; the proportion of polygonatum is 5%; and the proportion of emblica fructus is 5%.

[0009] Further preferably, the yam is iron stick yam; and the polygonatum is wild polygonatum.

[0010] The present invention also provides a method for preparing a composition for treating Alzheimer's disease, which is characterized in that the preparation method comprises: taking fresh guava, green papaya, yam, polygonatum, and emblica, sterilizing and crushing them after washing with pure water, and then inoculating lactobacillus, fermenting them in an insulated tank, and sterilizing them after ultrafiltration.

[0011] Preferably, the sterilization is carried out by pasteurization.

[0012] More preferably, the lactobacillus is plant lactobacillus, and its proportion is 5%.

[0013] Further preferably, the fermentation temperature is 5 degrees Celsius and the fermentation time is 72 hours.

[0014] Compared with the prior art, the present invention has the following advantages:

[0015] The composition for treating Alzheimer's disease provided by the present invention has been shown to have significant improvements in improving learning and memory ability and depression and anxiety levels through experimental results, and can effectively improve learning and memory and depression and anxiety of patients, and can be widely used in the treatment of Alzheimer's disease. The preparation method of the composition is also simple and effective. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments:

[0017] Figure 1 This is a statistical diagram of the total distance traveled in the open field experiment;

[0018] Figure 2 This is the distance statistics map of the central area of ​​the open field experiment;

[0019] Figure 3 This is the statistical diagram of the distance ratio in the central area of ​​the open field experiment;

[0020] Figure 4 This is a statistical chart of the number of times mice passed through the grid in the open field experiment;

[0021] Figure 5 This is the motion trajectory diagram of the open field experiment;

[0022] Figure 6 This is a statistical chart of latency time of mice in a water maze experiment with a platform;

[0023] Figure 7 This is a statistical diagram of the distance traveled by mice before they stepped onto the platform in a water maze experiment.

[0024] Figure 8 This is a statistical diagram of the initial movement direction of mice in a water maze experiment with a platform and the radian of the angle between the platform;

[0025] Fig. 9This is the movement trajectory of mice in the water maze experiment with a platform;

[0026] Fig.10 This is a statistical chart of the number of times mice crossed the platform in the water maze experiment without a platform;

[0027] Fig.11 This is a statistical chart of the swimming distance of mice in the quadrant where the platform is located in the water maze experiment without a platform;

[0028] Fig.12 This is the movement trajectory of mice in the water maze experiment without a platform;

[0029] Fig.13 This is the result of HE staining (magnification: 400X);

[0030] Fig.14 This is the movement trajectory diagram of C1 mouse water maze training;

[0031] Fig.15 This is the movement trajectory diagram of C1 mice during three formal tests. DETAILED DESCRIPTION

[0032] The following describes an embodiment of a composition for treating Alzheimer's disease and a preparation method thereof provided by the present invention in conjunction with the accompanying drawings.

[0033] This embodiment provides a composition for treating Alzheimer's disease, wherein the effective ingredients include guava, green papaya, Chinese yam, polygonatum, and emblica. The guava accounts for 40%; the green papaya accounts for 30%; the Chinese yam accounts for 20%; the polygonatum accounts for 5%; and the emblica accounts for 5%. The Chinese yam is Chinese yam with a stick of iron stick; and the polygonatum is wild polygonatum.

[0034] The preparation method of the composition for treating Alzheimer's disease comprises: taking 40% of fresh guava, 30% of green papaya, 20% of Chinese yam, 5% of wild polygonatum, and 5% of emblica, washing them with pure water, sterilizing them by pasteurization, crushing them, and then inoculating 5% of plant lactobacillus, and then fermenting them in a heat preservation tank at a temperature of 5 degrees Celsius for 72 hours, and sterilizing them after ultrafiltration.

[0035] Experimental methods:

[0036] Thirty C57BL / 6 male mice aged 6-7 weeks were housed in an SPF animal room and adapted to the environment for 3-5 days in advance.

[0037] The 30 mice were divided into 5 groups, namely, control group, model group, test drug treatment group, test drug prevention group, and positive drug (donepezil) control group. The control group consisted of 5 mice (4 mice after removing C1 mice), 6 mice in the model group, 5 mice in the test drug treatment group, 5 mice in the test drug prevention group, and 5 mice in the positive drug (donepezil) control group. The control group was treated with a drill to drill holes at the location and injected with 10 ml / kg (body weight) of PBS (PBS buffer, the most widely used buffer in biochemical research, with the main components of Na2HPO4, KH2PO4, NaCl and KCl) daily for 21 consecutive days; the model group was constructed with AD (Alzheimer's disease, Alzheimer's disease model, and 10 ml / kg (body weight) of PBS was gavaged daily one day after modeling for 21 consecutive days; the test drug treatment group was used to construct an AD model, and 10 ml / kg (body weight) of the composition for treating Alzheimer's disease of the present invention was gavaged daily one day after modeling for 21 consecutive days; the test drug prevention group was used to gavage the composition for treating Alzheimer's disease of the present invention for two consecutive weeks before AD modeling, and the rest of the treatment was the same as the treatment group; the positive drug (donepezil) control group was used to construct an AD model, and 45 mg / kg (body weight) of donepezil was gavaged daily one day after modeling for 21 consecutive days.

[0038] The AD model was constructed by injecting STZ (streptozotocin) into the lateral ventricle of mice. The concentration of STZ injection was 30ug / ul. 2.1g citric acid (FW: 210.14) and 2.94g sodium citrate (FW: 294.10) were diluted in 100ml distilled water to form liquid A and liquid B. Liquid A and liquid B were mixed 1:1 to form sodium citrate buffer. After the mouse was anesthetized, the fontanelle was exposed through a midline incision on the top of the lateral ventricle. STZ was slowly injected into the right ventricle for 5min (at a dose of 3mg / kg body weight) at a position below the anterior fontanelle, 1.5mm outside, 3.8mm deep, and 0.8mm behind. The needle stayed for 5min after injection, then slowly withdrew, and the wound was treated with penicillin and sutured.

[0039] The treatment group and the positive drug (donepezil) control group were gavaged every day for three consecutive weeks. The control group mice were gavaged with PBS every day, and the prevention group mice were gavaged two weeks before modeling. In order to simulate the human medication rhythm, the mice were gavaged at the time of turning off the lights every day, and the lights-off time was strictly controlled at 6 pm every day.

[0040] Behavioral testing:

[0041] Open field test: The experimental mice were allowed to acclimate in the testing room 1 hour before the formal test. The whole experiment was conducted in a quiet environment. An open field infrared tracking system was used to automatically record the autonomous activities of the mice within 5 minutes, analyze the movement distance of the mice and the movement distance in the central area, and then calculate the percentage of movement distance in the central area.

[0042] Water maze experiment: Before the water maze experiment, the mice to be tested were first trained for five days. During the experiment, the mice were placed in the quadrant opposite to the platform. If the mouse could reach the platform and stay on the platform for 3 seconds, it would stop automatically. If it could not find it, the mouse was manually helped to move to the platform for 10 seconds. Normal mice could gradually find the platform in the early stage of training. Then, in the formal free navigation test, the experimental table was removed and the mice were placed in another quadrant opposite to the experimental table, and their swimming trajectory, escape latency and other data were recorded.

[0043] After the behavioral experiment, the mice were deeply anesthetized using a gas anesthesia machine and then killed by cervical dislocation. The brain tissue of the mice was isolated and embedded, and then sliced ​​for HE staining.

[0044] HE detection: After collecting the mouse brain tissue, it was embedded in paraffin and then cut into 4-micron thick slices using a paraffin slicer. The slices were stained with hematoxylin-eosin and sealed transparently to observe the changes in cell morphology in the mouse hippocampus under a microscope.

[0045] Results and analysis:

[0046] Open field test: After the gavage treatment, five groups of mice were taken for open field test. The results showed that compared with the control group, the total movement distance of the model group mice was no different, but the central movement distance and the ratio of the middle distance decreased. In the treatment group mice, the total distance and central distance length of the mice increased compared with the model group, but the central distance ratio was no different. Compared with the model group, the total distance of the prevention group mice increased, and the central distance and central distance ratio decreased. There was no statistical difference between the three data of each group ( Figure 1-Figure 3 ), the statistical analysis of the number of grid penetrations showed that the number of grid penetrations in the model group was lower than that in the control group, and both the treatment group and the prevention group could increase the number of grid penetrations in the mice ( Figure 4 The typical movement trajectories of mice in each group are shown below ( Figure 5 ).

[0047] Water maze experiment with platform: After the gavage treatment and water maze training, five groups of mice were taken to conduct a water maze experiment with a platform. The results showed that compared with the control group mice, the model group mice had a longer latency period to find the platform, a longer distance before going on the platform, and a greater deviation in the initial direction. The three data of the treatment group mice improved, and there was almost no difference between the prevention group, the positive control group mice and the model group mice. There was no statistical difference between the three data of each group ( Figure 6-Figure 8 ), the typical movement trajectory of each group of mice is shown below ( Fig. 9 ).

[0048] Water maze experiment without platform: After the water maze experiment with platform, five groups of mice were taken to perform water maze experiment without platform. The results showed that compared with the control group mice, the model group mice crossed the platform less frequently and moved a shorter distance in the quadrant where the platform was located. These two data of mice in the treatment group and the prevention group were improved, and the improvement of mice in the treatment group was more obvious. There was almost no difference between the positive control group mice and the model group mice, and there was no statistical difference between the two data of each group ( Fig.10 , Fig.11 ), the typical movement trajectory of each group of mice is shown below ( Fig.12 ).

[0049] HE staining results: The results are as follows Fig.13 As shown in the figure, the magnification is 400 times, where Sham is the control group, AD is the model group, Treat is the treatment group, Prevention is the prevention group; Positive drug is the positive drug control group. HE staining showed that the neurons in the CA1 region of the hippocampus of the sham-operated group were round or oval, with neat cell morphology and a large number of neurons; compared with the sham-operated group, the cells in the CA1 region of the hippocampus of the model group were sparsely arranged, and the number of neurons was small; compared with the model group, the number of neurons in the CA1 region of the hippocampus of the treatment group, the prevention group and the positive drug group was more than that of the model group, with a more complete morphology and a more neat arrangement.

[0050] Supplementary data: Experimental results of excluding C1 mice from the control group Reason: C1 mice did not make any progress during the water maze training and only moved at the edge of the instrument, which was also the case in the formal experiment. In the open field experiment, the movement ability of this mouse was significantly worse than that of other control mice. This may be due to some damage caused by drilling holes in the skull or injecting PBS during the previous surgery. In order to avoid affecting the results, the data of this mouse was excluded from the analysis. Fig.14 is the motion track diagram of the mouse during training. Fig.15 These are the movement trajectories of the mouse in three formal experiments.

[0051] Test conclusion:

[0052] (1) The open field test is generally used to detect the depression and anxiety levels of mice. In this experiment, the detection indicators include the total distance traveled and the distance traveled in the central area. The higher the numbers of these two, the lower the depression level of the mouse. At the same time, the increase in the central area distance ratio can also indicate that the depression symptoms of the mouse are weakened. In addition, the number of times the mouse crossed the grid was counted. The number reflects the level of anxiety of the mouse. The more times the mouse crossed the grid, the weaker the anxiety symptoms of the mouse. Therefore, based on the experimental results, we concluded that:

[0053] ① The motor ability and depression level of mice in the treatment group were better than those in the model group, and their anxiety was also improved;

[0054] ②The depression level of mice in the prevention group did not change significantly, and their anxiety symptoms improved, but not as much as in the treatment group;

[0055] ③Compared with the positive drug control group, the treatment group can better improve the depression and anxiety levels of mice;

[0056] ④The prevention group was not as good as the positive drugs in improving depression levels, but was slightly better in anxiety treatment.

[0057] (2) Water maze experiments are generally used to detect the learning and memory abilities of mice. After training, mice will undergo tests with and without a platform. In the test with a platform, four data are recorded, including the time it takes for the mouse to get on the platform, i.e., the latency time. The shorter this data is, the better the mouse's memory is; the distance the mouse swims before getting on the platform. The lower this data is, the better the mouse's learning and memory abilities are; and the difference in curvature between the mouse's initial swimming direction and the remaining platforms. The smaller this data is, the better the mouse's learning and memory abilities are. In the test experiment without a platform, two indicators are recorded, namely, the number of times the mouse crosses the platform and the distance the mouse swims in the quadrant where the platform is located. The higher these two data are, the stronger the mouse's learning and memory abilities are. Therefore, based on the experimental results, we concluded that:

[0058] ① The learning and memory abilities of mice in the treatment group were significantly improved compared with those in the model group;

[0059] ② The learning and memory levels of mice in the prevention group were improved compared with those in the model group, but the magnitude was not as great as that in the treatment group;

[0060] ③Compared with the positive drug control group, the treatment group can significantly improve the learning and memory abilities of mice;

[0061] ④The prevention group was slightly better than the positive drug in improving learning and memory abilities, but the extent of improvement was not as great as that of the treatment group.

[0062] (3) HE staining analysis was used to detect the degree of neuronal damage in mice. Based on the results, we confirmed that both the treatment group and the prevention group could reduce the neuronal damage in mice. The degree of improvement in the two groups was similar, and there was no significant difference with the positive drug treatment group.

[0063] Summary: Overall, both the treatment group and the prevention group had therapeutic effects on the AD model. The treatment group was better than the prevention group and the positive drug (donepezil) treatment group in improving the learning and memory ability as well as the depression and anxiety levels of mice. There was not much difference between the prevention group and the positive drug treatment group.

Claims

1. A composition for treating Alzheimer's disease, characterized in that: The effective ingredients of the composition for treating Alzheimer's disease include guava, green papaya, yam, polygonatum and emblica.

2. A composition for treating Alzheimer's disease according to claim 1, characterized in that: The proportion of the guava is 40%; the proportion of the green papaya is 30%; the proportion of the yam is 20%; the proportion of the polygonatum is 5%; and the proportion of the emblica fruit is 5%.

3. A composition for treating Alzheimer's disease according to claim 1 or 2, characterized in that: The Chinese yam is Iron Stick Chinese yam; the Polygonatum sibiricum is wild Polygonatum sibiricum.

4. A method for preparing a composition for treating Alzheimer's disease according to any one of claims 1 to 3, characterized in that: The preparation method comprises: taking fresh guava, green papaya, yam, polygonatum and emblica, washing them with pure water, sterilizing and crushing them, inoculating lactobacillus, fermenting them in a heat preservation tank, and sterilizing them after ultrafiltration.

5. The method for preparing the composition for treating Alzheimer's disease according to claim 4, characterized in that: The sterilization is carried out by pasteurization.

6. The method for preparing the composition for treating Alzheimer's disease according to claim 4 or 5, characterized in that: The lactobacillus is plant lactobacillus, and its proportion is 5%.

7. A method for preparing a composition for treating Alzheimer's disease according to claim 4, 5 or 6, characterized in that: The fermentation temperature is 5 degrees Celsius and the fermentation time is 72 hours.

Citation Information

Patent Citations

  • Traditional Chinese medicine formula for treating senile dementia with syndrome of deficiency of liver-yin and kidney-yin

    CN105582296A

Cited By

  • Pharmaceutical composition for treating Alzheimer disease

    CN122478940A